Medicenna Therapeutics Valuation
| MDNA Stock | CAD 1.72 0.06 3.37% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Medicenna Therapeutics secures a last-minute Real Value of C$1.53 per share. The latest price of the firm is C$1.72. Our model forecasts the value of Medicenna Therapeutics from analyzing the firm fundamentals such as Return On Equity of -1.05, current valuation of 104.18 M, and Shares Owned By Insiders of 22.07 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Medicenna Therapeutics' valuation include:
Price Book 6.7041 | Enterprise Value 104.2 M | Enterprise Value Ebitda (6.11) | Forward PE 204.0816 |
Overvalued
Today
Please note that Medicenna Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Medicenna Therapeutics is based on 3 months time horizon. Increasing Medicenna Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Medicenna Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Medicenna Stock. However, Medicenna Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.72 | Real 1.53 | Hype 1.62 | Naive 2.07 |
The intrinsic value of Medicenna Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Medicenna Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Medicenna Therapeutics Corp helps investors to forecast how Medicenna stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medicenna Therapeutics more accurately as focusing exclusively on Medicenna Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Medicenna Therapeutics' intrinsic value based on its ongoing forecasts of Medicenna Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Medicenna Therapeutics' closest peers.
Medicenna Therapeutics Cash |
|
Medicenna Valuation Trend
Knowing Medicenna Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Medicenna Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Medicenna Therapeutics Total Value Analysis
Medicenna Therapeutics Corp is now estimated to have takeover price of 104.18 M with market capitalization of 139.12 M, debt of 13.94 M, and cash on hands of 33.6 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Medicenna Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
104.18 M | 139.12 M | 13.94 M | 33.6 M |
Medicenna Therapeutics Asset Utilization
One of the ways to look at asset utilization of Medicenna is to check how much profit was generated for every dollar of assets it reports. Medicenna Therapeutics Corp secures a negative usage of assets of -0.33 %, losing C$0.00328 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Medicenna Therapeutics Corp shows how discouraging it operates for each dollar spent on its assets.Medicenna Therapeutics Ownership Allocation
Medicenna Therapeutics maintains a total of 78.16 Million outstanding shares. Medicenna Therapeutics Corp holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Medicenna Therapeutics Profitability Analysis
Net Loss for the year was (25.47 M) with profit before overhead, payroll, taxes, and interest of 0.About Medicenna Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Medicenna Therapeutics Corp. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Medicenna Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Medicenna Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Medicenna Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Medicenna Therapeutics. We calculate exposure to Medicenna Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Medicenna Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -4.5 K | -4.7 K |
Other Information on Investing in Medicenna Stock
Medicenna Therapeutics financial ratios help investors to determine whether Medicenna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicenna with respect to the benefits of owning Medicenna Therapeutics security.